China Securities Co. sees pharma momentum carrying into 2027, urges focus on innovation and global expansion

Stock News11-12

According to a research report released by China Securities Co., Ltd., the pharmaceutical sector's operations continued to improve through the first three quarters of 2026, and this trend is expected to extend into 2027.

Looking ahead to 2027, overseas clinical trials and registrations for innovative drugs are entering a phase of intensive validation. With growing outbound expansion and the rise of strategic alliances, companies will face a larger market alongside a more complex competitive landscape, with both opportunities and risks coexisting. For CXO players, order conversion and recovering upstream demand are reinforcing each other, while AI-driven drug discovery (AIDD) is further boosting demand. Device companies are gradually showing signs of an earnings inflection point; traditional Chinese medicine and pharmaceutical distribution players should be watched for operational recovery, while blood products and vaccines are focused on new products, consolidation and overseas expansion. The report advises investors to seize opportunities centered on innovation and internationalization, while paying greater attention to the theme of marginal improvement.

Innovative drugs: internationalization enters the validation phase, focus on clinical and commercialization delivery

Outbound expansion of innovative drugs has entered a phase of global Phase III data validation, where opportunities and risks coexist and competition is escalating; leading players in segmented tracks are preferred. Investment opportunities in 2027 will come from validation of overseas expansion and changes in the competitive landscape. In 2026, business development (BD) has upgraded into "strategic alliances," and 2027 will see the initial testing of these alliances, which is expected to unlock new global value.

CXO and upstream: orders continue to be delivered, domestic substitution and AI demand resonate

CXO demand is steady and improving, with orders translating into revenue and profit; scarce capacity and business inflection points warrant attention. Domestic substitution of upstream equipment and consumables is accelerating, and scientific reagents stand to benefit from the recovery of early-stage research and the development of AI pharma, extending the trend of profit recovery.

Medical devices and services: inflection points gradually emerging, capture innovation and overseas expansion

Quarterly results for device companies continue to improve; watch for the clearing of centralized procurement impacts and the ramp-up of innovative products, with long-term optimism on surgical robots, brain-computer interfaces and internationalization. Medical services are focused on the recovery of ophthalmic demand and the repair brought by refined operations.

Pharmaceutical consumption and biological products: watch for recovery, consolidation and new product ramp-up

Traditional Chinese medicine's dividend attributes are becoming more prominent; watch for channel improvements and basic drug list catalysts. Retail pharmacies are expected to see same-store growth and valuation repair, while distribution players should be watched for improved receivables collection. Blood products are focused on industry consolidation, new products and overseas expansion, while vaccines warrant attention on innovative pipelines and overseas markets.

Investment recommendation: position around innovation and internationalization, increase focus on the marginal improvement theme

For 2027, innovative drugs are recommended as the main line for growth elasticity, innovative drugs and device internationalization as the main line for value realization, and pharmacies, IVD, traditional Chinese medicine, distribution and medical services as the main lines for marginal improvement and valuation repair. Overall, investors should balance growth elasticity with delivery capability, preferring segmented leaders with differentiated pipelines, globalization capabilities, order visibility and certainty of operational improvement.

Risk factors: fiercer-than-expected competition, industry policy risks, risks of R&D falling short of expectations, risks of approvals falling short of expectations, macroeconomic volatility risks, and geopolitical risks.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment